Notizie AIOM – anno XVI n. 670

10 Aprile 2018

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

In two phase III studies, nivolumab, a programmed death-1 (PD-1) inhibitor antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non–small-cell lung cancer (NSCLC). We report 5-year follow-up results from an early phase I study of nivolumab ...
Leggi tutto

9 Aprile 2018

FDA Grants Fast Track Designation for TAR-200 in Muscle-Invasive Bladder Cancer

April 6, 2018 - On April 3, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TAR-200, a gemcitabine-releasing intravesical system (GemRIS), for the treatment of patients with organ-confined or locally advanced muscle-invasive bladder cancer ...
Leggi tutto

9 Aprile 2018

FDA Expands Rucaparib Approval to Include Maintenance Treatment of Recurrent Ovarian Cancer

April 6, 2018 - Today, the U.S. Food and Drug Administration (FDA) approved rucaparib tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based ...
Leggi tutto

9 Aprile 2018

6 aprile 2018 – Chiusura Registro di monitoraggio Sorafenib (Bayer AG) (RCC)

9 Aprile 2018

6 aprile 2018 – Chiusura Registro di monitoraggio Sorafenib (Bayer AG) (epatocarcinoma)

9 Aprile 2018

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial

Given the cumulative neurotoxicity associated with oxaliplatin, a shorter duration of adjuvant therapy, if equally efficacious, would be advantageous for patients and health-care systems. The Three or Six Colon Adjuvant trial is an open-label, phase III, multicenter, noninferiority ...
Leggi tutto

9 Aprile 2018

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. In International Duration Evaluation of Adjuvant Chemotherapy (IDEA) France, as part ...
Leggi tutto

9 Aprile 2018

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, ...
Leggi tutto

6 Aprile 2018

EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

April 5, 2018 - On April 3, the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC ...
Leggi tutto

6 Aprile 2018

AAD Issues Guidelines for Treatment of Nonmelanoma Skin Cancer

April 2, 2018 - Skin cancer is the most common cancer in the United States, and nonmelanoma skin cancer is the most common type of skin cancer, affecting more than 3 million Americans every year. Moreover, nonmelanoma skin cancer incidence is growing at an exponential rate ...
Leggi tutto

LAVORIAMO CON

News

ICTUS, SCARSA QUALITÀ DELLA VITA NEL POST RIABILITAZIONE PER 1 PAZIENTE SU 4

SCOPERTE 74 REGIONI DNA LEGATE A METABOLISMO E CHILI DI TROPPO

BRISTOL MYERS SQUIBB OTTIENE L’APPROVAZIONE DELLA COMMISSIONE EUROPEA PER NIVOLUMAB NEL TRATTAMENTO ADIUVANTE DI PAZIENTI CON TUMORE ESOFAGEO O DELLA GIUNZIONE GASTRO-ESOFAGEA CON MALATTIA PATOLOGICA RESIDUA DOPO CHEMIO-RADIOTERAPIA

ACTO LOMBARDIA RINNOVA GLI APPUNTAMENTI CON “LA CASA DELLE DONNE”

ACTO PUGLIA PORTA “MOVIMENTO E SALUTE” IN REGIONE

CELGENE, ORA PARTE DI BRISTOL-MYERS SQUIBB, ANNUNCIA I RISULTATI PRELIMINARI DELLO STUDIO A LUNGO TERMINE CHE RAFFORZANO IL PROFILO DI EFFICACIA E SICUREZZA DI OZANIMOD NEI PAZIENTI CON FORME RECIDIVANTI DI SCLEROSI MULTIPLA

POLIAMBULANZA, 20 POSTI LETTO PER I PAZIENTI SUB ACUTI PRESSO LA RSA KORIAN “COSI’ PROVIAMO A SUPERARE I LIMITI IMPOSTI DALLA PANDEMIA”

Notizie AIOM – anno XVI n. 670

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

FDA Grants Fast Track Designation for TAR-200 in Muscle-Invasive Bladder Cancer

FDA Expands Rucaparib Approval to Include Maintenance Treatment of Recurrent Ovarian Cancer

6 aprile 2018 – Chiusura Registro di monitoraggio Sorafenib (Bayer AG) (RCC)

6 aprile 2018 – Chiusura Registro di monitoraggio Sorafenib (Bayer AG) (epatocarcinoma)

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

AAD Issues Guidelines for Treatment of Nonmelanoma Skin Cancer